J.P. Morgan Reiterates Overweight on Nektar Therapeutics

J.P. Morgan is out with its report today on Nektar Therapeutics NKTR, reiterating Overweight. In a note to clients, J.P. Morgan writes, "We have an OW rating on NKTR as we see it as an attractive long term biotech holding. Our view is based the potential of the company to leverage its novel polymer conjugation technology platform into a broad and diversified product pipeline. Wholly owned NKTR-102 is the focus of most investors, but the company also has meaningful shots on goal with other mid-to-late stage partnered assets, including NKTR-118 and Inhaled Amikacin." Shares of NKTR closed Tuesday at $8.24, down 0.11% from Monday's close.